In brief the rationale for the use of mixtures is as follows: The renal toxicity of most of the newer sulphonamides, if used singly, is due primarily to over-saturation of the tubular urine with a sparingly soluble sulphonamide and/or its metabolic product, resulting in the formation and deposition of drug crystals in the urinary pathways (crystalluria) . This event may be followed by haematuria, oliguria, and complete renal shutdown. If instead of a single sulphonamide a combination of partial dosages of several therapeutically equivalent sulphonamides is employed, the danger of crystal formation in the kidney from the drugs comprising the mixture is significantly reduced. In fact, it will be only as great as if each compound had been administered alone and in the partial dosage contained in the mixture, since sulphonamides of different molecular structure, even if closely related, can be dissolved simultaneously to the full extent of their individual solubilities. At the same time full therapeutic potency is retained, since the antibacterial effect of such combinations is completely additive and may in many instances even show potentiation of action in vitro as well as at the bedside.1 2 15 From the standpoint of renal protection, combinations of substantially equal partial dosages of at least three sulphonamides were considered adequate in routine therapy in the absence of alkalization.'8 Some objection has been voiced against the use of mixed sulphonamides on theoretical grounds. It was intimated that the concomitant use of several drugs may lead to the simultaneous development of allergy against more than one component of the mixture. 19 Thus the incidence of allergic reactions might be increased and the possibility of "switching" a sensitized patient to another sulphonamide drug might be eliminated.
This thought was based on the concept that the incidence of sensitization to sulphonamides is largely independent of the dosage used. However, this point of view is not borne out by practical experience. Critical evaluation of the vast literature on sulphonamide therapy12 demonstrated that, in the dosage range employed in human prophylaxis and therapy, the incidence of sensitization increases in direct proportion with the dosage. provided medication was maintained for a minimum of three to five days. These observations indicate that the production of sensitization reactions is dependent upon the repeated presence of certain minimal tissue concentrations of a sulphonamide for a minimum period of several days.
In most patients sensitization is specifically limited to the sulphonamide used. Hence the simultaneous administration of several sulphonamides in partial dosage may result in a reduced rather than an increased incidence of sensitization because mixtures permit " dilution " of individual drug concentrations below the level necessary for the production of allergy.
This concept appeared to be substantiated by our experience with more than 700 patients treated with combinations of two or three sulphonamides, including sulphadiazine, sulphamerazine, sulphapyrazine, sulphacetamide, and the " worst offender " sulphathiazole. The incidence of drug rash and fever at the full therapeutic dosage of 6 g. in 24 hours was impressively low and nowhere exceeded
2%.12
It has yet to be established whether closely related compounds such as isomers and homologues -e.g., sulphadiazine, sulphapyrazine, sulphamerazine, and sulphamezathine (sulphadimidine)-can be distinguished by the cells of the body as specific haptens. Should The behaviour of the other six drugs in the human body, as gleaned from the extensive literature on this subject, is illustrated in Table III drug are there stressed by bold print. Distinct drawbacks are indicated by italics. It can be seen that sulphadiazine is the least plasma-bound, best-diffusing, and least acetylated of the four " diazines." Hence, sulphadiazine rightfully maintains a therapeutic advantage over sulphamerazine and a definite superiority over sulphamezathine and sulphapyrazine. Sulphathiazole shares the disadvantage of excessive plasma-binding with the three last-named drugs and manifests in addition particularly poor diffusion into the cerebrospinal canal. Sulphacetamide, on the other hand, except for low blood levels due to rapid excretion, exceeds even the merits of sulphadiazine with regard to conjugation, diffusion, and plasma-binding.
No substantial differences seem to exist among systemic sulphonamides concerning their antibacterial spectrum. It should be remembered that various sulphonamides possessing a free para-amino group do not display appreciable differences in bacterial affinities. Molecular Although the sulphapyrazine and sulphamezathine combinations show higher blood levels, the sulphacetamide mixture, which is a close third in this respect, stands out as the one with excellent tissue distribution. In fact, the diffusion of this drug mixture into lungs and brain slightly surpasses that of the sulphapyrazine combination and is distinctly higher than that of the sulphamezathine or sulphathiazole mixture.
Similar results were achieved in 70 rabbits in studies of tissue distribution of sulphonamides from various routes of administration. In addition spinal fluid was obtained in these animals by occipital puncture, so that the blood-spinal-fluid ratio could be calculated. From the oral route of administration the diffusion of the sulphadiazine-sulphamerazine-sulphacetamide mixture through the haematocephalic barrier was as good as that of sulphadiazine, and the absolute concentration in the spinal fluid and blood even somewhat higher than that from sulphadiazine alone.
In the chronic study (Fig. 2) around 30-40%, which was less than could be expected on the basis of mathematical computation using the figures of the single drugs. Since, in our hands, a combination of sulphadiazine-sulphamerazine-sulphathiazole had given excellent therapeutic results at the bedside, it was expected that the replacement of sulphathiazole by sulphacetamide would not interfere with the therapeutic efficiency of the triple mixture.
Clinical Application of Triple Mixtures Clinical trials with a combination of equal partial amounts of sulphadiazine-sulphamerazine-sulphacetamide have been completed. A total of 170 unselected patients of all age groups with serious acute infections have undergone this therapy at the full routine dosage (in children: 0.15 to 0.2 g./kg. body weight daily; in adults: 3-4 g.
initially, 4-6 g. daily thereafter ; the lower maintenance dose of 4 g. daily proved adequate in most instances). Blood levels were excellent. They ranged as a rule between 10 and 25 mg. of free sulphonamide per 100 ml. Acetylation was low, rarely exceeding 20-25% in the blood and 40% in the urine. Although no alkalizing agents were used, crystalluria of a moderate degree was encountered in only 12 instances, as a rule in connexion with excessive urine concentrations of sulphonamide. There were two cases of drug rash and fever occurring on the tenth and the -thirteenth day of therapy, respectively, and two instances of fever alone, possibly due to sulphonamide administration. One patient with acute tonsillitis had severe nausea and vomiting on the third day of drug administration, requiring interruption of therapy, and another patient with pneumonia developed a moderate degree of "cyanosis" apparently due to the drug. No other serious untoward reactions were observed. Therapeutic results were highly satisfactory, with defervescence usually occurring within the first 24 to 48 hours. The series comprised 55 cases of bacterial pneumonia, 23 of shigellosis (Shigella sonnei), six of pyelitis, five of bacterial meningitis, one of penicillin-resistant pneumococcal bacteriaemia, and one of penicillin-and streptomycinresistant staphylococcal septicaemia.
The experimental and clinical evaluation of other sulphonamide mixtures is continuing at present. Summary The simultaneous administration of several sulphonamides in partial dosage may result in a reduced rather than an increased incidence of sensitization, because mixtures permit "dilution " of individual drug concentrations below the level necessary for the production of allergy. Hence it is possible to enhance the renal protection afforded by sulphonamide mixtures by using additional components in proportionately smaller amounts, without the danger of increasing the incidence of allergic reactions.
Sulphadiazine and sulphamerazine qualify for first and second place, respectively, as mixture components. Sulphathiazole, sulphapyrazine, sulphamezathine, and sulphacetamide deserve attention as possible third and fourth members of a combination. Although sulphathiazole has fallen into disfavour in the U.S.A. because of its high clinical toxicity, mixtures containing this drug have shown a low overall toxicity. Sulphapyrazine, the most insoluble of these compounds, induces frequent renal and allergic reactions and therefore offers no advantages over sulphathiazole. Sulphamezathine has adequate solubility and low toxicity, but is subject to substantial conjugation and plasma-binding, which diminish its therapeutic efficiency. Sulphacetamide retains the high solubility of stilphanilamide and shares with the parent compound the improbability of renal concretion formation and the ready diffusibility into all tissues. In addition, it shows low figures for conjugation, plasmabinding, and sensitization.
The mixture sulphadiazine-sulphamerazine-sulphacetamide (equal amounts) revealed low toxicity in animals as well as excellent bacteriostatic activity in vitro and in experimental infections of mice. After oral administration, blood and spinalfluid levels were similar to those from equal doses of sulphadiazine or sulphamerazine. Clinical trials of this mixture in 170 patients with acute systemic infections showed a high curative value and low toxicology. Pulmonary hydatid cysts, apart from the rare cases which heal spontaneously after a single or repeated expectoration, are exclusively in the domain of surgery, varying only in the details of technique suited to each case. Encouraged by the good results obtained in severe broncho-pulmonary suppurations, both localized and diffuse, by our method of transthoracic intrapulmonary injections of sulphonamides, antibiotics, and other drugs, we extended this treatment to suppurations due to the retention of hydatid membranes-that is, to suppurating cysts of the lung with incarcerated membranes. A few years later, in view of our favourable experience with infected cysts, we applied the same method of treatment to clean uninfected hydatid cysts.
Without exaggeration, and on the basis of our case records, we can now say that some cases can be treated medically. The importance and scope of this treatment remain to be established by further experience. Whilst the results in cases followed up have so far been successful, their number is too small to warrant definite conclusions. Nevertheless, we are optimistic, since we cannot believe that only the favourable cases came into our hands.
These cases fall into three categories: (1) suppurating pulmonary hydatid cysts, with retained membranes; (2) ruptured pulmonary hydatid cysts, with loss of fluid content and persistence of the parasitic cavity, whether air-containing or not; and (3) hyaline hydatid cysts-that is, closed and non-infected. We will outline the therapeutic procedures employed in each category, and give a single example of each kind to show the more salient clinical features.
Suppurating Pulmonary Hydatid Cysts, with Retained Membranes These cases present two problems: broncho-pulmonary suppuration and the retention or incarceration of the parasitic membranes. The first problem is really a consequence of the second, since the membranes, except in rare instances of clean encystment or of calcification, behave as true foreign bodies, leading sooner or later to pus formation in the surrounding parenchyma.
We treat pulmonary suppuration locally by means of transthoracic injections of sulphonamides and antibiotics, choosing the drug according to the organism isolated, whenever possible, from the material aspirated, and adapting the dosage, interval of administration, etc., to the clinical and radiological progress of the patient.
The complete expulsion of the membranes, which is essential to end the suppuration, is achieved by a purely mechanical effect. The local congestion, partly hydrostatic and partly biochemicals created by the transthoracic injection provokes intense and repeated bouts of coughing, which directs the fluid current towards bronchi already dilated as a result of the suppuration. This flow carries along with it fragments of endocyst which have been *A paper to be read at the First International Congress of Internal Medicine, Paris, September 11-14, 1950.
